SBTX

Silverback Therapeutics, Inc. [SBTX] Stock Forecast

Q: What is Silverback Therapeutics, Inc. stock symbol ?

Silverback Therapeutics, Inc. is a US stock, located in Seattle of Wa and trading under the symbol SBTX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

SBTX Stock Summary

The Moving Average Convergence Divergence (MACD) for SBTX recently turned positive (within last 10 days).

SBTX has less than 1 year of cash runway

In the News

08:22 16 Apr 2024 SBTX

Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins

Penny stocks to watch right now The post Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:20 16 Apr 2024 SBTX

Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce

Silverback Therapeutics Inc (NASDAQ: SBTX) undertakes “strategic realignment,” revealing it would drop its two lead cancer programs and lays off more than a quarter of its staff. Silverback will continue the advancement of early-stage discovery research.

07:11 16 Apr 2024 SBTX

Silverback Therapeutics shuts down oncology program, plans to lay off 27% of workforce

Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter earnings report.

06:15 16 Apr 2024 SBTX

Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

04:07 16 Apr 2024 SBTX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX

New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Silverback and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...

05:56 16 Apr 2024 SBTX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX

New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Silverback and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information...

11:23 16 Apr 2024 SBTX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX

NEW YORK, Sept. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX).

07:45 16 Apr 2024 SBTX

Silverback Therapeutics Presents Initial Safety Data From Solid Tumor Combo Therapy Trial

Silverback Therapeutics Inc (NASDAQ: SBTX) has presented interim data from a Phase 1/1b study of SBT6050 as a monotherapy and in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab). Data were shared at the 2021 European Society for Medical Oncology Congress (ESMO21).

03:30 16 Apr 2024 SBTX

Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today presented interim clinical results from a Phase 1/1b clinical study of SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced

08:03 16 Apr 2024 SBTX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX

NEW YORK, Sept. 14, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX).

SBTX Financial details

Company Rating

Buy

Market Cap

550.43M

Income

-14.69M

Revenue

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

29 Mar 2023

P/E

-26098.92

Forward P/E

PEG

2550.33

P/S

P/B

2117.95

P/C

P/FCF

-16.77

Quick Ratio

26.89

Current Ratio

27.18

Debt / Equity

LT Debt / Equity

EPS (TTM)

0.72

EPS next Y

EPS next Q

EPS this Y

-97.24%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

SMA20

14.29%

SMA50

14.29%

SMA100

Inst Own

0.06%

Inst Trans

1.02%

ROA

-8%

ROE

-8%

ROC

-0.11%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

93.77M

Shs Float

11.64M

Target Price

52W Range

2.8-7.545

52W High

-16.14%

52W Low

+193.5%

RSI

Rel Volume

0.68

Avg Volume

171.42K

Volume

116.69K

Perf Week

-25.7%

Perf Month

-18.81%

Perf Quarter

Perf Half Y

Beta

Volatility

0.84%, 0.66%

Prev Close

-31.98%

Price

5.87

Change

-28.68%

SBTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-3.59	-4.9	-11.33	-30.81	-0.85
Operating cash flow per share	-3.45	-3.86	-10.73	-22.96	-1
Free cash flow per share	-3.54	-3.88	-11.04	-23.43	-1.01
Cash per share	4.12	2.04	132.95	87.37	6.87
Book value per share	-7.15	-12.01	131.68	107.93	6.83
Tangible book value per share	-7.15	-12.01	131.68	107.93	6.83
Share holders equity per share	-7.15	-12.01	131.68	107.93	6.83
Interest debt per share	0.58	2.35	1.08	2.05	-0.01
Market cap	122.33M	122.33M	134.74M	19.36M	234.54M
Enterprise value	109.9M	127.97M	-247.77M	-228.83M	24.5M
P/E ratio	-6.96	-5.1	-4.09	-0.22	-6.93
Price to sales ratio	0	0	0	0	0
POCF ratio	-7.25	-6.47	-4.32	-0.29	-5.85
PFCF ratio	-7.06	-6.44	-4.2	-0.28	-5.82
P/B Ratio	-3.5	-2.08	0.35	0.06	0.86
PTB ratio	-3.5	-2.08	0.35	0.06	0.86
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-6.43	-5.46	7.67	2.58	-0.69
EV to operating cash flow	-6.51	-6.77	7.94	3.43	-0.61
EV to free cash flow	-6.34	-6.74	7.72	3.36	-0.61
Earnings yield	-0.14	-0.2	-0.24	-4.63	-0.14
Free cash flow yield	-0.14	-0.16	-0.24	-3.52	-0.17
Debt to equity	-0.08	-0.2	0.01	0.02	0
Debt to assets	0.1	0.74	0.01	0.02	0
Net debt to EBITDA	0.73	-0.24	11.84	2.8	5.91
Current ratio	4.04	0.59	40.69	17.56	51.01
Interest coverage	0	0	1.14K	-843.13	42.59
Income quality	0.96	0.79	0.95	0.75	1.16
Dividend Yield	0	0	0	0.04	0
Payout ratio	0	0	0	-0.01	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.03	0.01	0.03	0.02	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.94	-0.18	-1.44	-1.75	-0.62
Stock based compensation to revenue	0	0	0	0	0
Graham number	24.04	36.38	183.23	273.54	11.41
ROIC	0.7	0.56	-0.08	-0.27	-0.13
Return on tangible assets	-0.64	-1.53	-0.08	-0.27	-0.12
Graham Net	-8.66	-13.17	128.85	80.62	6.65
Working capital	15.63M	-7.4M	381.06M	246.6M	272.26M
Tangible asset value	-34.98M	-58.78M	382.88M	313.82M	272.89M
Net current asset value	-41.75M	-63.9M	378.73M	241.84M	269.15M
Invested capital	-0.08	-0.2	0.01	0.02	0
Average receivables	0	0	0	0	0
Average payables	0	2.15M	3.05M	2.33M	1.04M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0.5	0.41	-0.09	-0.29	-0.12
Capex per share	-0.09	-0.02	-0.32	-0.47	0

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.53	0.72	0	0	0
Operating cash flow per share	-0.47	0.29	0	0	0
Free cash flow per share	-0.47	0.3	0	0	0
Cash per share	7.52	6.87	0	0	0
Book value per share	7.53	6.83	0	0	0
Tangible book value per share	7.53	6.83	0	0	0
Share holders equity per share	7.53	6.83	0	0	0
Interest debt per share	0.04	-0.03	0	0	0
Market cap	187.22M	234.54M	553.11B	557.13B	561.03B
Enterprise value	-15.79M	24.5M	553.03B	557.01B	560.97B
P/E ratio	-2.47	2.04	-12.34K	-8.02K	-9.43K
Price to sales ratio	0	0	0	0	0
POCF ratio	-11.29	20.58	-44.5K	1.56M	0
PFCF ratio	-11.25	19.74	-43.82K	1.56M	0
P/B Ratio	0.7	0.86	2.12K	2.24K	2.36K
PTB ratio	0.7	0.86	2.12K	2.24K	2.36K
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	0.95	0.97	-29.55K	-27.04K	-31.2K
EV to operating cash flow	0.95	2.15	-44.49K	1.56M	0
EV to free cash flow	0.95	2.06	-43.81K	1.56M	0
Earnings yield	-0.1	0.12	0	0	0
Free cash flow yield	-0.09	0.05	0	0	0
Debt to equity	0	0	0	0	0
Debt to assets	0	0	0	0	0
Net debt to EBITDA	12.17	-8.34	4.67	5.76	3.35
Current ratio	67.87	51.01	27.18	25.37	21.87
Interest coverage	-15.62	-17.03	4.99	0	0
Income quality	0.93	0.42	0.83	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.04	0.02	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.65	-2.27	-9.65	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	9.51	10.52	0	0	0
ROIC	-0.07	0.1	-0.05	-0.08	-0.08
Return on tangible assets	-0.07	0.1	-0.04	-0.07	-0.06
Graham Net	7.41	6.65	0	0	0
Working capital	266.81M	272.26M	257.51M	244.98M	233.29M
Tangible asset value	267.07M	272.89M	261.16M	248.55M	237.28M
Net current asset value	266.81M	269.15M	257.31M	244.83M	233.19M
Invested capital	0	0	0	0	0
Average receivables	0	0	0	0	0
Average payables	1.12M	63K	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	10.37	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	8.68	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.07	0.11	-0.04	-0.07	-0.06
Capex per share	0	0.01	0	0	0

SBTX Frequently Asked Questions

What is Silverback Therapeutics, Inc. stock symbol ?

Silverback Therapeutics, Inc. is a US stock , located in Seattle of Wa and trading under the symbol SBTX

What is Silverback Therapeutics, Inc. stock quote today ?

Silverback Therapeutics, Inc. stock price is $5.87 today.

Is Silverback Therapeutics, Inc. stock public?

Yes, Silverback Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 171.42K
Market Capitalization 550.43M
Employee 90
CEO Dr. Peter A. Thompson M.D.
Headquarters Seattle,WA,US
IPO Date 2020-12-03
Website https://www.silverbacktx.com

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.